生命科学资讯
生物技术与制药领域的最新动态
Amgen jilts Kyowa, exiting $400M autoimmune pact after running vast pivotal program
Chugai drops only AI-assisted antibody from pipeline but still holds high hopes for tech
Moderna's latest CMO steps down after barely a year
Moderna以5000万美元预付款将晚期罕见病药物转让给Recordati。
Moderna offloads late-stage rare disease drug to Recordati for $50M upfront
阿斯利康以185亿美元重返中国石药集团达成肥胖症药物交易。
AstraZeneca returns to China's CSPC for $18.5B obesity deal
Formation Bio继续在华大举收购，斥资5亿美元达成自身免疫性疾病生物技术协议。
Formation Bio’s China shopping spree continues with $500M biobucks autoimmune pact
罗氏诊断业务在2025年微增2%，中国市场逆风冲击亚太区销售。
Roche diagnostics business nudges up 2% in '25 as China headwinds buffet Asia-Pacific sales
比利时生物技术公司Agomab拟纳斯达克上市融资2.12亿美元，支持免疫学试验。
Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials
赛诺菲放弃开发下一代mRNA季节性流感疫苗。
Sanofi abandons attempt to develop next-gen mRNA seasonal flu vaccine
赛诺菲对与Denali合作前景保持沉默，终止RIPK1抑制剂后未透露计划。
Sanofi keeps mum on future of disappointing Denali pact after scrapping final RIPK1 inhibitor
阿斯利康承诺在华投资150亿美元，增强细胞疗法与放射性药物研发能力。
AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities
礼来加入Repertoire合作阵容，与大型药企达成价值高达26.9亿美元的自免疾病协议。
Repertoire adds Lilly to range of Big Pharma partners in autoimmune deal worth up to $2.69B
生物医药并购新规：今年推动交易的四大趋势
The new rules of biopharma M&A: 4 trends driving dealmaking this year
查尔斯河实验室新任CEO表示，减少动物实验是生命科学研发领域的"渐进式变革而非革命性突破"。
Reducing animal testing 'an evolution and not a revolution' for life sci R&D, Charles River's incoming CEO says
新型化合物使小鼠脑肿瘤缩小，为胶质母细胞瘤口服药带来希望。
New compound shrinks brain tumors in mice, sparking hope for a glioblastoma pill
Eikon计划在即将到来的股市首秀中筹集2.74亿美元。
Eikon sets $274M goal for upcoming stock market debut
Halozyme乘并购浪潮，以高达4亿美元收购Surf Bio，强化递送技术布局。
Halozyme catches M&A wave to snap up Surf Bio in delivery tech deal worth up to $400M
礼来与德国生物科技公司签署11亿美元协议，合作研发听力损失基因编辑疗法。
Lilly pens $1.1B pact with German biotech to work on gene editing med for hearing loss
报告称：2025年医疗科技并购"回暖"，估值走软加剧交易竞争。
Medtech M&A 'rebounded' in 2025 as softer valuations drove deal competition: report